Skip to main content
. 2022 Nov 30;13:1027577. doi: 10.3389/fphar.2022.1027577

FIGURE 9.

FIGURE 9

A working model of irigenin in GBM cells. Irigenin treatment inhibited the YAP/β-catenin pathway in GBM cells, which may result in inhibiting the tumorigenesis, including inhibition of cell proliferation, suppression of the migration, and induction of the apoptosis both in vitro and in vivo.